pre- and post-allohsct treatment in mds
Published 3 years ago • 68 plays • Length 5:43Download video MP4
Download video MP3
Similar videos
-
3:16
developing patient-specific mrd markers for predicting and preventing mds relapse post-sct
-
6:20
maintenance therapy after allogeneic hsct in mds
-
1:12
managing gvhd in patients undergoing sct
-
2:35
methods of optimizing transplantation in mds
-
1:52
advances in lr-mds and hr-mds in 2023 and beyond
-
2:15
optimizing transplantation for mds
-
1:56
incorporating novel agents for myelofibrosis in the pre- and post-transplant settings
-
8:14
progress in the treatment of tp53 mutated aml
-
7:11
treatment of older mds patients with bmt (bone marrow transplantation)
-
3:41
treatment of anemia in lr-mds: luspatercept and imetelstat
-
1:13
horizon scan of mds treatments
-
0:59
bmt ctn 1102: pre-transplantation qol measures improve prognostication in hr-mds
-
1:31
pevaz update: pevonedistat & azacitidine in r/r mds and mds/mpn after dnmti failure
-
1:59
topics of interest in mds: the role of maintenance therapy, immune checkpoints & ven-aza in hr-mds
-
2:08
hematological response to frontline treatment in lr-mds is associated with better os
-
3:17
pre-mds states: novel therapeutic approaches, and determining appropriate trial endpoints
-
1:04
the current standard of care for mds-related cytopenias and how treatment strategies may evolve
-
2:04
state-of-the-art treatment for hr-mds
-
4:31
labmt: impact of treatment prior to allogenic hct in mds
-
3:31
relevance of the ipss-r during sct in patients with mds in the molecular classification era
-
2:44
the impact of mutation screening on transplant decisions in mds
-
3:37
progress in the categorization and treatment of lr-mds